Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference32 articles.
1. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer;Modijtahedi;Int J Oncol,1994
2. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers;Gullick;Br Med Bull,1991
3. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit Rev Oncol Hematol,1995
4. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors;Rusch;Cytokine Growth Factor Rev,1996
5. Targeting the epidermal growth factor for chemotherapy of carcinomas;Davies;Biochem Pharmacol,1996
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Epigenetic regulation in lung cancer;MedComm;2023-10-26
2. Historical development of EGFR-targeted therapy;Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC;2023
3. Clinical Strategies for Developing Next-Generation Cancer Precision Medicines;Essentials of Bioinformatics, Volume II;2019
4. Precision oncology: neither a silver bullet nor a dream;Pharmacogenomics;2017-11
5. MatchMiner: An open source computational platform for real-time matching of cancer patients to precision medicine clinical trials using genomic and clinical criteria;2017-10-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3